INDIA- Pharmaceutical giant AstraZeneca India has launched a partnership with respiratory healthcare platform Alveofit to provide IoT-enabled handheld spirometers at hospitals across the nation.
This initiative strives to integrate the most recent technological breakthroughs in order to diagnose and treat lung illnesses and related non-communicable diseases like asthma.
Alveofit IoT-enabled handheld spirometers will facilitate tele spirometry with integrated care management systems and assist in patient tracking remotely.
AstraZeneca has installed spirometers in a few hospitals across India, including state-run Government hospitals, command and military hospitals, general hospitals, and clinics.
Before launching this program, 2800+ patients were tested as part of a pilot experiment, and 35–40% of those, ranging in age from 10–12 years old to 85–90 years old, were found to have lung problems.
“AstraZeneca continues to prioritize our aim to minimize the burden of lifestyle disorders and Non-communicable diseases (NCDs) on the healthcare systems through significant interventions and partnerships,” stated Dr. Anil Kukreja, President of Medical Affairs & Regulatory at AstraZeneca India.
Alveofit-AstraZeneca collaboration is enabling the basic respiratory disease diagnostics affordable and accessible at the last mile in public health infrastructure as well as through the corner clinics
He believes that early diagnosis of respiratory distress minimizes emergency hospital visits, and regular monitoring of lung functions and ongoing communication with healthcare professionals improve treatment effectiveness overall.
His team is strongly committed to innovating and discovering strategies for creating a sustainable means to advance, enhance, and scale up holistic respiratory treatment throughout the nation.
He further states that the collaboration with Alveofit is a decisive step in their shared effort to decrease respiratory illnesses, complications, and morbidity rates by continuously monitoring patients and enhancing respiratory health for all.
“Alveofit-AstraZeneca collaboration is enabling the basic respiratory disease diagnostics affordable and accessible at the last mile in public health infrastructure as well as through the corner clinics,” stated Dr. Prashant Patel, founder, and CEO of Alveofit.
He added that given the characteristics of their living and working environments, these diseases disproportionately afflict the low-income population.
By developing new tools, AstraZeneca is assisting people in taking control of their own health, through the use of tools that enable people to actively participate in their own health.
In order to make basic respiratory diagnosis and care available to everyone, AstraZeneca and Alveofit intend to extend this project to tier-2 and tier-3 communities throughout India.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
